Comparison of felodipine extended release and conventional tablets in essential hypertension using ambulatory blood pressure monitoring
- PMID: 2681410
- DOI: 10.1097/00004872-198908000-00008
Comparison of felodipine extended release and conventional tablets in essential hypertension using ambulatory blood pressure monitoring
Abstract
Two formulations of felodipine, conventional and extended release (ER) tablets, were compared in a double-blind, crossover study of patients whose blood pressure was not being controlled using metoprolol 100 mg once daily. Nineteen patients with a supine diastolic blood pressure greater than or equal to 95 mmHg after 4 weeks of taking metoprolol and placebo were randomly assigned to felodipine conventional (5 mg twice a day) or ER (10 mg once daily) for 4 weeks. A 2-week washout period was then followed by 4 weeks of treatment with the alternative formulation. Metoprolol once daily was taken concomitantly throughout the study. Clinic blood pressure was measured at 0 h (i.e. 12 h after the last dose of conventional, and 24 h after the last ER felodipine dose), and then 2 and 5 h after the following dose had been taken. Ambulatory blood pressure and the heart rate were monitored over 24 h using an Accutracker (Suntech Medical Instruments, Raleigh, North Carolina, USA). During the final treatment, both felodipine formulations caused similar substantial falls in supine blood pressure compared with pressures prior to randomized treatment. The falls in clinic blood pressures (systolic/diastolic) were similar with the conventional and ER formulations at all time points, i.e. 0 h (21/13; 19/11 mmHg), 2 h (39/18; 36/18 mmHg) and 5 h (30/12; 35/11 mmHg) after the morning dose was taken. Both formulations also produced similar falls in blood pressures over 24 h and during the daytime (21/12; 20/12 mmHg).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.Drugs. 1992 Aug;44(2):251-77. doi: 10.2165/00003495-199244020-00008. Drugs. 1992. PMID: 1382018 Review.
-
Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone.Blood Press Suppl. 1993;1:37-45. Blood Press Suppl. 1993. PMID: 8173689 Clinical Trial.
-
The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients.Eur J Clin Pharmacol. 2000 Nov;56(8):529-35. doi: 10.1007/s002280000198. Eur J Clin Pharmacol. 2000. PMID: 11151741 Clinical Trial.
-
Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine.Eur J Clin Pharmacol. 1992;42(1):25-30. doi: 10.1007/BF00314915. Eur J Clin Pharmacol. 1992. PMID: 1541312 Clinical Trial.
-
Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension.Am J Med. 1992 Aug 31;93(2A):56S-64S. doi: 10.1016/0002-9343(92)90295-m. Am J Med. 1992. PMID: 1519637 Review.
Cited by
-
Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard.Br J Clin Pharmacol. 1990 Dec;30(6):871-8. doi: 10.1111/j.1365-2125.1990.tb05453.x. Br J Clin Pharmacol. 1990. PMID: 2288833 Free PMC article. Clinical Trial.
-
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.Drugs. 1992 Aug;44(2):251-77. doi: 10.2165/00003495-199244020-00008. Drugs. 1992. PMID: 1382018 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical